Merus Announces IND Clearance for MCLA-145
MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137
UTRECHT, The Netherlands, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for MCLA-145, a first-in-class PD-L1 x CD137 Biclonics® being developed in collaboration with Incyte (Nasdaq: INCY), for the treatment of solid tumors.
“We are pleased to announce the IND authorization to proceed from the FDA and to disclose more details around our latest Biclonics® program today,” said Andres Sirulnik, M.D., Ph. D., Executive Vice President and Chief Medical Officer of Merus. “Our preclinical work has demonstrated that MCLA-145 has the potential to overcome the known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents. We expect to initiate the clinical trial program for MCLA-145 during the second quarter of 2019 and we look forward to continuing our collaboration with Incyte on MCLA-145’s global development.”
Discovered through an unbiased functional screening of multiple immunomodulatory target combinations, MCLA-145 is a Biclonics® T-cell agonist that binds with high affinity and specificity to human PD-L1 and CD137 in preclinical models. The unique immunostimulatory profile of MCLA-145 derives from the ability to potently activate immune effector cells in the context of the tumor microenvironment while simultaneously blocking inhibitory signals in the same immune cell population.
Merus is developing MCLA-145 as part of a collaboration entered into with Incyte in December 2016 to potentially develop and commercialize up to 11 bispecific and monospecific antibodies from the Merus Biclonics® platform. Under the terms of the collaboration, Merus will retain all rights to develop and commercialize MCLA-145, if approved, in the United States, while Incyte has rights to develop and commercialize MCLA-145, if approved, outside the United States.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the characteristics and immunostimulatory profile of MCLA-145; the potential for MCLA-145 to overcome known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents; the commencement and timing of the clinical trial program for MCLA-145; the continuing collaboration with Incyte on MCLA-145’s global development, and potential to develop and commercialize up to 11 bispecifc and monospecific antibodies from the Merus Biclonics® platform; and whether any of the programs under the collaboration will be successful, including for MCLA-145. .
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics® and bispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaboration with Incyte or Incyte may fail to perform adequately under our collaboration; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 28, 2017, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor and Media Inquiries:
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
GOGL - 2020 Annual General Meeting8.7.2020 20:36:21 CEST | Press release
Golden Ocean Group Limited (the “Company”) advises that the 2020 Annual General Meeting of the Company will be held on August 31, 2020. The record date for voting at the Annual General Meeting is set to July 17, 2020. The notice, agenda and associated material will be distributed prior to the meeting. Hamilton, Bermuda July 08, 2020 This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Avance - 2020 Annual General Meeting8.7.2020 19:38:30 CEST | Press release
Avance Gas Holding Ltd (the “Company”) advises that the 2020 Annual General Meeting of the Company will be held on August 31, 2020. The record date for voting at the Annual General Meeting is set to July 17, 2020. The notice, agenda and associated material will be distributed prior to the meeting. Hamilton, Bermuda July 8, 2020 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
FRO - 2020 Annual General Meeting8.7.2020 19:18:32 CEST | Press release
Frontline Ltd. (the “Company”) advises that the 2020 Annual General Meeting of the Company will be held on August 31, 2020. The record date for voting at the Annual General Meeting is set to July 17, 2020. The notice, agenda and associated material will be distributed prior to the meeting. Hamilton, Bermuda July 8, 2020 This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Flex LNG - AGM Notice8.7.2020 19:00:00 CEST | Press release
Flex LNG Ltd. (NYSE and OSE: FLNG) (“FLNG” or the “Company”) advises that the 2020 Annual General Meeting of the Company will be held on August 31, 2020. The record date for voting at the Annual General Meeting is set to July 17, 2020. The notice, agenda and associated material will be distributed prior to the meeting. July 8, 2020 The Board of Directors Flex LNG Ltd. Hamilton, Bermuda
Orion upgrades full-year outlook for 20208.7.2020 18:00:00 CEST | Press release
ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION 8 JULY 2020 at 19.00 EEST Orion upgrades full-year outlook for 2020 Orion Corporation upgrades the full-year outlook for 2020, provided on 24 April 2020, for the part regarding operating profit. In 2020, the operating profit is estimated to be slightly higher or higher than in 2019. Visibility towards the end of the year has improved in various areas of operations. For example, the impaired availability of generic products in Orion‘s portfolio manufactured by other pharmaceutical companies is not expected to have as negative impact to the whole year net sales and operating profit as assumed earlier. Operating expenses, in turn, for the whole year are expected to be somewhat lower than estimated. The new outlook is based on the assumption that Orion‘s own production can continue normal operations despite the COVID-19 pandemic. This requires that Orion continues to succeed in protecting its employees and employee absence rates d
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING8.7.2020 16:20:00 CEST | Press release
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-07-10 Transaction type:SEK CreditTender date:2020-07-10Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-07-14Final repayment date2024-07-15Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON JULY 10 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: firstname.lastname@example.org Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at http://www.riksbank.se